The collaboration aims to combine Immune Disease Institute (IDI) immunological expertise with GlaxoSmithKline’s (GSK’s) pharmaceutical capabilities within a competitive framework. The partnership will be pioneering in the way it allows researchers at both institutions to develop joint grant proposals in targeted areas of research under an innovative and competitive Alliance Research grant program.
In addition to the substantial scientific benefits brought by a long-term synergy with world class immunologists, GSK will receive an exclusive right of first negotiation for a substantial portion of the new technologies discovered and disclosed by IDI scientists during the term of the agreement. The research term for the collaboration is five years and will be anchored through GSK’s Immuno-Inflammation Centre of Excellence in Drug Discovery.
Jose Carlos, senior vice president of GSK, said: “This agreement fits perfectly with our strategy to pursue scientific excellence and technologies both internally and externally. The best science coming from IDI and the best drug discovery capabilities from GSK will produce transformative medicines that will change patients lives.”